Objective: Adiponectin has been proposed to be related to endothelial function. We have examined the relationship between the increase in adiponectin levels that is associated with troglitazone treatment and endothelium-dependent vasodilation in type 2 diabetic patients.
Research Methods And Procedures: Seventy-two patients participated in this randomized, placebo-controlled, double-blinded study. High-resolution ultrasound images were used to measure the flow-mediated dilation (endothelium-dependent) and nitroglycerin-induced dilation (endothelium-independent) of the brachial artery. Laser Doppler perfusion imaging was employed to measure the vascular reactivity in the forearm skin.
Results: Troglitazone treatment resulted in an average 75% increase in the adiponectin levels, but no changes were observed in the endothelium-dependent vasodilation, any other measurement of vascular reactivity, or any other markers of endothelial activation. Also, no changes were observed in the expression of the receptor for advanced glycation end-products in skin biopsies taken from the forearm. Significant correlations were observed during troglitazone treatment between the changes in the adiponectin levels and the changes in fasting plasma glucose (r = -0.29, p < 0.05), hemoglobin A(1c) (r = -0.30, p < 0.05), total cholesterol (r = 0.25, p < 0.05), and low-density lipoprotein-cholesterol (r = 0.34, p < 0.01).
Discussion: The increase in adiponectin levels after troglitazone treatment is not associated with an improvement in the endothelium-dependent vasodilation, indicating that adiponectin is not a major determinant of endothelial function. In addition, receptor for advanced glycation end-products expression in the skin microcirculation is not affected by troglitazone treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/oby.2005.138 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Thiazolidinedione derivatives in cancer therapy: exploring novel mechanisms, therapeutic potentials, and future horizons in oncology.
Naunyn Schmiedebergs Arch Pharmacol
December 2024
Department of Pharmacy, School of Health Sciences, Central University of South Bihar, Gaya, 824236, India.
Thiazolidinedione derivatives have shown significant potential as targeted cancer therapies by leveraging their various mechanisms of action. These include suppressing cell proliferation, triggering apoptosis, and influencing signaling pathways associated with tumor development. Their multifaceted effects make them promising candidates for advancing cancer treatment strategies.
View Article and Find Full Text PDFTroglitazone reduces intracellular Mycobacterium tuberculosis survival via macrophage autophagy through LKB1-AMPKα signaling.
J Infect Dis
October 2024
National Clinical Research Center for Infectious Diseases, Guangdong Provincial Clinical Research Center for Tuberculosis, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, 518112, China.
Tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb), results in significant morbidity and mortality worldwide. Host-directed therapy (HDT), including conventional drugs, is a promising anti-TB strategy that shows synergistic antibacterial effects when combined with anti-TB drugs. Here, the mycobactericidal effect of three anti-diabetic drugs was examined.
View Article and Find Full Text PDFUnveiling the shield: Troglitazone's impact on epilepsy-induced nerve injury through ferroptosis inhibition.
CNS Neurosci Ther
August 2024
Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, P.R. China.
Article Synopsis
- Epilepsy affects around 50 million people worldwide, with many patients facing drug-refractory conditions despite available anti-epileptic drugs, indicating a need for new treatment options.
- This study investigates troglitazone (TGZ) as a potential neuroprotective agent against seizures and neuronal damage, employing both in vitro and in vivo models to assess its effects.
- Results showed that TGZ significantly reduced seizure severity and neuronal damage by inhibiting ferroptosis, preventing mitochondrial changes, and demonstrating efficacy in both cell models of toxicity.
Protocol to create phenotypic primary human hepatocyte cultures using the RASTRUM 3D cell model platform.
STAR Protoc
September 2024
Inventia Life Science, Alexandria, NSW 2015, Australia. Electronic address:
To improve human hepatotoxicity prediction, in vitro liver cell models replicating hepatocyte function, drug metabolism, and toxicity are required. Here, we present a protocol for creating 3D primary human hepatocyte (PHH) cell models using the RASTRUM Platform. We describe the process for PHH model generation; procedures for characterizing the PHH model, including viability, albumin production, and CYP450 inducibility; and drug treatment using acetaminophen and troglitazone.
View Article and Find Full Text PDFUncovering the mechanism of troglitazone-mediated idiosyncratic drug-induced liver injury with individual-centric models.
Arch Toxicol
November 2024
PredictCan Biotechnologies SAS, Biopôle Euromédecine, 1682 Rue de La Valsière, 34790, Grabels, France.
Idiosyncratic drug-induced liver injury is a rare and unpredictable event. Deciphering its initiating-mechanism is a hard task as its occurrence is individual dependent. Thus, studies that utilize models that are not individual-centric might drive to a general mechanistic conclusion that is not necessarily true.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!